Publication of preclinical findings for ATXA Therapeutics' NTP42

ATXA Therapeutics have published a new paper detailing results of its lead drug candidate NTP42 in a preclinical model of pulmonary...

100 Hot Start Ups.

The companies driving Ireland's entrepreneurial edge. ATXA Therapeutics Ltd is delighted to be recognised amongst such a fantastic list...

ATXA & PAH- Hope attend ERS Congress 2019 in Madrid

We’re here at the ERS Congress 2019 where we will be presenting the our preclinical findings of NTP42 for the treatment of PAH. Please...

ATXA attends the ESC Congress 2019 in Paris

We're here! Drop by the Poster Area for the session on "Pulmonary Arterial Hypertension ‑ Treatments" and talk to us about our...

ESC Congress Paris 2019

ATXA Therapeutics and PAH-Hope team members, Prof. Therese Kinsella & Dr. Helen Reid are looking forward to the ESC Congress 2019 next...

Experimental and Molecular Pathology

Use the link below to read or download ATXA Therapeutics published article on the expression and regulation of thromboxane receptors in...

New paper on thromboxane receptors in prostate inflammation published in Experimental and Molecular

ATXA Therapeutics, along with members of the academic research group of CSO Prof. Therese Kinsella at University College Dublin, have...

EIC Welcomes Entrepreneurs

PAH-HOPE CSO Prof. Therese Kinsella is in Brussels meeting fellow entrepreneurs in the EIC community at SME Phase 2 Coordinators Welcome...

ATXA is on a mission !

Funding Opportunities for Breakthrough Innovation

ATXA Therapeutics Founder and CSO, Prof Therese Kinsella will represent the company at an event on the European Innovation Council...

Irish life sciences start-ups to watch

ATXA Therapeutics Ltd is proud to be listed among the 10 interesting Irish life sciences start-ups to watch. New hope for the PAH...

COMPANY UPDATES